Ralinepag vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Reported efficacy
Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)
Result source: NCT03626688
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
NCT03399604 · Phase 3 · completed
The study was an open-label, single-group trial with 121 participants and no placebo or active comparator. Its primary endpoint was treatment-emergent and serious adverse events, rather than a controlled clinical efficacy outcome, so the findings provide limited evidence about the treatment’s comparative effectiveness.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Reported efficacy
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events (Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 16 months.): LIQ861 Inhaled Treprostinil 121 Participants (not_applicable)
Result source: NCT03399604
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Ralinepag: 4 of 4 rows · Treprostinil (Yutrepia, Liquidia): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ralinepag | Treprostinil (Yutrepia, Liquidia) |
|---|---|---|
| Dropout rate | 44.4%a NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result15% NCT02279160 · Phase 2 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result24%LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Discontinued due to AEs | 15.6%a NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result— NCT02279160 · Phase 2 · registry result, not featured evidence | —LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Serious AEs | 46.7%a NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result10% NCT02279160 · Phase 2 · registry result, not featured evidence | 12.4%LIQ861 Add-On NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 show 1 more result—LIQ861 Inhaled Treprostinil NCT03399604 · Phase 3 · Pulmonary Arterial Hypertension · phase 3 |
| Most frequent reported AEs | a headache 64.4% diarrhoea 37.8% pain in jaw 33.3% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 77.5% (placebo 28.6%) nausea 50% (placebo 23.8%) diarrhoea 47.5% (placebo 14.3%) NCT02279160 · Phase 2 · registry result, not featured evidence | cough 33.9% headache 19% upper respiratory tract infection 14.9% NCT03399604 · Phase 3 · add on · Pulmonary Arterial Hypertension · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ralinepag
show 16 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Yutrepia, Liquidia)'s landscape